Newar Giraldo, General Manager of Humax in Colombia, discusses the company’s role in countering monopolistic situations, their recent focus on OTC medicines, as well as their selective internationalization strategy based on regulatory fit, and his intention to enter the nanotechnology and biosimilar sectors.
Could you introduce our readers to the company’s activities?
"We are selective when it comes to our internationalisation strategy. Our priority is to make sure the products have a good regulatory fit with the country."
